AR077901A1 - Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer - Google Patents

Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer

Info

Publication number
AR077901A1
AR077901A1 ARP100103069A ARP100103069A AR077901A1 AR 077901 A1 AR077901 A1 AR 077901A1 AR P100103069 A ARP100103069 A AR P100103069A AR P100103069 A ARP100103069 A AR P100103069A AR 077901 A1 AR077901 A1 AR 077901A1
Authority
AR
Argentina
Prior art keywords
diagnosis
antibody
cmet
prognosis
oncogenic
Prior art date
Application number
ARP100103069A
Other languages
English (en)
Spanish (es)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR077901A1 publication Critical patent/AR077901A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • G01N33/57496
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ARP100103069A 2009-08-21 2010-08-23 Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer AR077901A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23586409P 2009-08-21 2009-08-21
EP09305777A EP2287197A1 (en) 2009-08-21 2009-08-21 Anti-cMET antibody and its use for the detection and the diagnosis of cancer
US34800510P 2010-05-25 2010-05-25

Publications (1)

Publication Number Publication Date
AR077901A1 true AR077901A1 (es) 2011-09-28

Family

ID=41571045

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103069A AR077901A1 (es) 2009-08-21 2010-08-23 Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer

Country Status (19)

Country Link
US (2) US8673302B2 (2)
EP (2) EP2287197A1 (2)
JP (1) JP5951486B2 (2)
KR (1) KR20120051734A (2)
CN (1) CN102639564B (2)
AR (1) AR077901A1 (2)
AU (1) AU2010284944B2 (2)
BR (1) BR112012003759A2 (2)
CA (1) CA2769427C (2)
ES (1) ES2692522T3 (2)
IL (1) IL218202A (2)
IN (1) IN2012DN01322A (2)
MX (1) MX2012002139A (2)
NZ (2) NZ700437A (2)
RU (1) RU2582265C2 (2)
SG (1) SG178339A1 (2)
TW (1) TW201111781A (2)
WO (1) WO2011020925A1 (2)
ZA (1) ZA201202076B (2)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR20130103734A (ko) 2010-08-31 2013-09-24 제넨테크, 인크. 바이오마커 및 치료 방법
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 HGF 활성을 가지는 c-Met에 대한 인간항체 및 이의 용도
AU2012312515A1 (en) 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 c-Met의 SEMA 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2782932A1 (en) 2011-11-21 2014-10-01 F.Hoffmann-La Roche Ag Purification of anti-c-met antibodies
ES2736999T3 (es) * 2011-11-21 2020-01-09 Taivex Therapeutics Corp Biomarcadores para cánceres que responden a moduladores de la actividad de Hec1
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
JP6129956B2 (ja) * 2012-05-09 2017-05-17 イーライ リリー アンド カンパニー 抗c−Met抗体
WO2013192594A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
WO2015031626A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015032695A1 (en) * 2013-09-09 2015-03-12 Ventana Medical Systems, Inc. Scoring method for mesothelin protein expression
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Axlに対するヒトモノクローナル抗体
EP3253791A1 (en) * 2015-02-03 2017-12-13 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-rho gtpase conformational single domain antibodies and uses thereof
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
MX382582B (es) * 2015-03-18 2025-03-13 Seagen Inc Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados.
JP6669882B2 (ja) * 2016-02-05 2020-03-18 ヘリックスミス カンパニー リミテッド 抗−c−MET抗体及びその用途
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
RU2735918C2 (ru) * 2018-06-07 2020-11-10 Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" Набор реагентов для выявления маркера эпителиальных карцином
JP7332194B2 (ja) * 2018-06-29 2023-08-23 スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド Pd-l1結合ポリペプチドおよびそれらの使用
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
EP3980783A4 (en) * 2019-06-06 2023-09-13 Apollomics Inc. (Hangzhou) Method for treating cancer patients using c-met inhibitor
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
EP4129335A4 (en) 2020-09-01 2024-04-24 RemeGen Co., Ltd. ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS
JP2023541011A (ja) * 2020-09-08 2023-09-27 イデアヤ、バイオサイエンシズ、インコーポレイテッド 医薬組み合わせおよび腫瘍治療
AU2023283550A1 (en) * 2022-06-09 2024-11-21 Santa Ana Bio, Inc. Antibodies targeting c-kit and/or siglec and uses thereof
CA3263050A1 (en) 2022-07-30 2024-02-08 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradation and their methods of use
IL326548A (en) * 2023-08-14 2026-04-01 Minghui Pharmaceutical Hangzhou Ltd Nanoantibody against C-MET and its use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
AU2002357388A1 (en) * 2001-12-27 2003-07-24 The United States Of America, As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
WO2007056523A2 (en) * 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing and monitoring the progression of cancer
CA2638889C (en) * 2006-02-06 2015-06-02 Metheresis Translational Research S.A. Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer

Also Published As

Publication number Publication date
NZ598194A (en) 2015-05-29
CN102639564A (zh) 2012-08-15
US8673302B2 (en) 2014-03-18
AU2010284944B2 (en) 2016-01-28
JP5951486B2 (ja) 2016-07-13
KR20120051734A (ko) 2012-05-22
US20140295452A1 (en) 2014-10-02
WO2011020925A1 (en) 2011-02-24
IN2012DN01322A (2) 2015-06-05
SG178339A1 (en) 2012-03-29
AU2010284944A1 (en) 2012-03-08
ES2692522T3 (es) 2018-12-04
CA2769427C (en) 2020-03-10
CN102639564B (zh) 2015-01-07
EP2287197A1 (en) 2011-02-23
ZA201202076B (en) 2012-11-28
BR112012003759A2 (pt) 2017-07-11
JP2013502213A (ja) 2013-01-24
RU2582265C2 (ru) 2016-04-20
NZ700437A (en) 2016-04-29
EP2467402A1 (en) 2012-06-27
IL218202A0 (en) 2012-04-30
IL218202A (en) 2017-07-31
MX2012002139A (es) 2012-03-07
US20120149031A1 (en) 2012-06-14
RU2012109004A (ru) 2013-09-27
CA2769427A1 (en) 2011-02-24
TW201111781A (en) 2011-04-01
EP2467402B1 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
AR077901A1 (es) Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer
AR081696A1 (es) Anticuerpo para el diagnostico y/o pronostico de cancer
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
IL201778A0 (en) Peptide imaging agents
MX366965B (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
NI201200014A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina - 2 humana
MX383886B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
GB0718967D0 (en) Peptide imaging agents
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
EA201490825A8 (ru) Tdp-43-специфически связывающие молекулы
BRPI0720371B8 (pt) métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
EP3885366A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
BR112016005802A2 (pt) conjugados de clorotoxina e métodos de seu uso
MX337666B (es) Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas.
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
MX2010004671A (es) Seprasa como marcador para cancer.
EA201291044A1 (ru) Слитый белок robo1-fc и его применение в лечении опухолей
AR063493A1 (es) Nuevos anticuerpos anti notch 3 y su uso para la deteccion y el diagnostico de enfermedades
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
MX2012002909A (es) Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
CY1119430T1 (el) Anti-s100a7 αντισωματα για τη θεραπευτικη αγωγη και διαγνωση καρκινου

Legal Events

Date Code Title Description
FA Abandonment or withdrawal